GE HealthCare
GEHC
$70.31
+0.10%
GE HealthCare Technologies is a leading medical technology company specializing in imaging, ultrasound, patient care solutions, and pharmaceutical diagnostics, operating in the healthcare information services industry. As a market leader in imaging and ultrasound equipment, it holds a distinct competitive position with a diversified revenue stream across four major segments and a global footprint spanning the US, EMEA, China, and other regions. The current investor narrative centers on the company's growth trajectory amid cost inflation pressures, as evidenced by a recent guidance cut due to $250 million in cost inflation, while the stock has experienced significant volatility, including a sharp decline in late April 2026 followed by a partial recovery. Investors are closely watching how GE HealthCare navigates these margin headwinds while capitalizing on its recurring revenue base and innovation in digital and AI-driven healthcare solutions.…
GEHC
GE HealthCare
$70.31
Related headlines
Investment Opinion: Should I buy GEHC Today?
We rate GEHC a Hold. The stock offers a 20% upside to the average analyst target of $81.72, but the recent guidance cut and margin pressures warrant caution. The consensus is 'Buy', but the stock's underperformance and high forward P/E (12.6x) imply market skepticism. Key supports include a 7.4% revenue growth, a 13.4% operating margin, and a 20.1% ROE, but these are offset by cost inflation and decelerating growth. The rating would upgrade to Buy if the company demonstrates margin recovery and revenue acceleration above 10%, or downgrade to Sell if growth falls below 5% and margins continue to compress. Currently, the stock is fairly valued relative to its history, trading at a discount to the industry P/E of 22x.
Sign up to view all
GEHC 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While the stock is undervalued relative to peers and has a strong analyst consensus, the guidance cut and margin pressures create uncertainty. The key factor is whether the company can offset cost inflation and maintain growth. If margins recover and growth stabilizes, the stock could re-rate upward; otherwise, it may continue to underperform. I would upgrade to bullish if Q2 earnings show margin improvement, and downgrade to bearish if growth falls below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $82.50 and implied upside of +17.3% versus the current price.
Average Target
$82.50
0 analysts
Implied Upside
+17.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $96
Analyst target range
Analyst coverage is robust with 18 analysts, and the consensus recommendation is 'Buy' with a mean rating of 1.74 (where 1 is Strong Buy and 5 is Sell). The average target price is $81.72, implying an upside of approximately 20% from the current price of $68.02. The distribution shows a bullish tilt, with 10 recent ratings including upgrades from UBS (Neutral from Sell) and Goldman Sachs (Neutral from Buy), though the latter is a downgrade, indicating mixed sentiment. The target range spans from $67.00 low to $96.00 high, with the high target suggesting potential for significant recovery if the company successfully navigates cost pressures and accelerates growth, while the low target reflects downside risks from continued margin compression and competitive challenges. The wide spread of $29 between low and high targets signals high uncertainty about the company's near-term outlook, consistent with the recent guidance cut and volatile price action.
Bulls vs Bears: GEHC Investment Factors
GE HealthCare presents a mixed picture: it offers a leading market position, a recurring revenue base, and a valuation discount to peers, but faces near-term margin headwinds from cost inflation and decelerating growth. The bear case is currently stronger due to the guidance cut and stock's persistent underperformance, but the bull case hinges on successful cost management and execution. The key tension is whether the company can offset inflation and reaccelerate growth to justify its forward P/E, which will determine the stock's direction over the next 12 months.
Bullish
- Undervalued vs. Industry Peers: GEHC trades at a trailing P/E of 18.0x, an 18% discount to the industry average of 22x. This suggests the market is pricing in conservative expectations, providing a margin of safety for investors.
- Strong Analyst Consensus and Upside: With 18 analysts, the consensus rating is 'Buy' (mean 1.74) and the average target price is $81.72, implying ~20% upside from the current price of $68.02. The high target of $96 suggests even greater potential if execution improves.
- Solid Revenue Growth: Q1 2026 revenue grew 7.4% YoY to $5.13B, driven by imaging and ultrasound leadership. This growth, while decelerating, outpaces the broader medical device sector and supports the company's competitive position.
- Recurring Revenue Base: Approximately 50% of revenue is recurring (service, pharmaceutical diagnostics, digital), providing stability and visibility. This recurring stream cushions against cyclical equipment sales and supports long-term cash flow.
Bearish
- Guidance Cut Due to Cost Inflation: The company lowered 2026 earnings guidance due to $250M in cost inflation, which long sales cycles make difficult to offset. This has pressured margins and raised concerns about near-term profitability.
- Decelerating Growth Trajectory: Q1 2026 revenue growth of 7.4% YoY is down from prior quarters, and sequential revenue has plateaued around $5.1B. This deceleration suggests the company may struggle to maintain momentum.
- Significant Underperformance vs. Market: GEHC's 1-year price change is -4.6% versus the S&P 500's +18.2%, a relative underperformance of -22.8%. This reflects persistent bearish sentiment and a lack of investor confidence.
- High Valuation on Forward Earnings: The forward P/E of 12.6x implies ~43% earnings growth, which is aggressive given the guidance cut. If earnings fail to meet expectations, the stock could face de-rating.
GEHC Technical Analysis
GE HealthCare's stock is in a clear downtrend over the past year, with a 1-year price change of -4.6%, significantly underperforming the S&P 500's +18.2% gain. The current price of $68.02 sits at approximately 31% of its 52-week range (between $58.75 low and $89.77 high), indicating the stock is trading near the lower end of its yearly range, which often signals either a value opportunity or persistent bearish sentiment. The stock's relative strength over 1 year is -22.8%, confirming its weak performance relative to the market, and the 6-month change of -13.9% further underscores the prolonged downward pressure.
Beta
0.82
0.82x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
+0.5%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | +8.4% | +2.8% |
| 3m | +10.8% | +4.2% |
| 6m | -12.8% | +11.3% |
| 1y | +0.5% | +21.5% |
| ytd | -15.1% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
GE HealthCare's revenue trajectory shows mixed but generally positive growth, with the most recent quarter (Q1 2026) reporting revenue of $5.131 billion, a 7.4% year-over-year increase. However, this growth rate is decelerating from the prior year's levels, as Q1 2025 revenue was $4.777 billion, and the sequential trend shows quarterly revenues of $5.143 billion (Q3 2025) and $5.006 billion (Q2 2025), indicating a plateau. The imaging segment remains the largest driver at $2.299 billion, followed by PCS at $704 million and PDx at $770 million, but the overall growth is being tempered by cost inflation and long sales cycles, as highlighted in the recent guidance cut.
Quarterly Revenue
$5.1B
2026-03
Revenue YoY Growth
+7.4%
YoY Comparison
Gross Margin
38.5%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Given GE HealthCare's positive net income, the primary valuation metric selected is the P/E ratio. The trailing P/E stands at 18.0x, while the forward P/E is 12.6x, implying the market expects earnings growth of approximately 43% over the next year, which is aggressive given the recent guidance cut. Compared to the industry average P/E of 22x (based on available data), GE HealthCare trades at a discount of about 18%, which could indicate undervaluation or reflect the market's skepticism about future growth. Historically, the stock's P/E has ranged from 12x to 50x over the past two years, with the current 18x near the lower end of that band, suggesting the market is pricing in conservative expectations relative to its own history.
PE
18.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, GEHC faces margin pressure from $250M in cost inflation, which has already led to a guidance cut. The company's operating margin of 13.4% is below its historical levels, and with a debt-to-equity of 0.96, interest expenses of $96M in Q1 2026 could rise if rates stay high. Free cash flow of $1.52B provides some buffer, but continued inflation could erode profitability. Revenue concentration in imaging (45% of revenue) exposes the company to cyclical equipment demand, and the deceleration in growth (7.4% YoY in Q1 2026) suggests potential market saturation.
FAQ
The key risks include: 1) Financial: cost inflation of $250M could further compress margins, and high debt (D/E 0.96) increases interest expense. 2) Competitive: intense competition from Siemens and Philips in imaging could pressure market share. 3) Macro: rising interest rates could increase borrowing costs and compress valuation multiples. 4) Company-specific: decelerating revenue growth (7.4% YoY) and long sales cycles may hinder the ability to offset inflation. The most severe risk is a continued margin decline leading to a drop toward the 52-week low of $58.75, a potential -13.6% downside.
The 12-month forecast is mixed. In the bull case (25% probability), the stock could reach $80-$96 if margins recover and growth accelerates. In the base case (50% probability), it may trade in the $70-$82 range, aligning with the average analyst target of $81.72. In the bear case (25% probability), it could fall to $58-$67 if cost inflation persists and growth decelerates. The most likely scenario is the base case, assuming the company stabilizes margins and maintains ~7% growth.
GEHC trades at a trailing P/E of 18.0x, an 18% discount to the industry average of 22x, suggesting it is undervalued relative to peers. However, its forward P/E of 12.6x implies the market expects ~43% earnings growth, which is aggressive given the guidance cut. Historically, the stock's P/E has ranged from 12x to 50x, and the current 18x is near the lower end, indicating the market is pricing in conservative expectations. Overall, the stock appears fairly valued to slightly undervalued, but the low forward P/E reflects skepticism about future growth.
GEHC offers a 20% upside to the average analyst target of $81.72, and its trailing P/E of 18x is below the industry average of 22x. However, the recent guidance cut due to $250M cost inflation and decelerating growth (7.4% YoY) introduce significant risk. For investors with a medium-term horizon and tolerance for volatility, GEHC could be a good buy if they believe management can offset inflation. For those seeking near-term certainty, it may be prudent to wait for evidence of margin recovery.
GEHC is better suited for long-term investment (3-5 years) given its leading market position and recurring revenue base, which provide a foundation for growth. The stock's beta of 0.84 indicates lower volatility than the market, but its recent price swings (e.g., -32.5% max drawdown) suggest short-term trading is risky. The company's growth stage and earnings visibility support a long-term hold, but investors should monitor margin recovery and competitive dynamics. A minimum holding period of 3 years is recommended to ride out near-term volatility.